Test ID: FHFIB
Hepatitis C Virus (HCV) FibroSURE
Clinical and Interpretive
Fees and Coding
Excel | PDF
Setup Reference Guide
Assessment of Liver status following a diagnosis of HCV. Baseline
determination of liver status before initiating HCV therapy. Post-
treatment assessment of liver status six months after completion of
therapy. Non-invasive assessment of liver status in patient
who are at increased risk of complications from a liver biopsy.
TESTS REFERENCE INTERVAL
HCV FibroSURE Results:
Fibrosis Score 0.00 - 0.21
Necroinflammat Activity Score 0.00 - 0.17
Necroinflammat Activity Grade
Alpha-2-Macroglobulins, Qn 110 - 276 mg/dL
Haptoglobin 34 – 200 mg/dL
Apolipoprotein A-1 Females: 110 – 205 mg/dL
Males: 110 – 180 mg/dL
Newborns, term and near term:
24 hours old: 0.0 – 8.0 mg/dL
48 hours old: 0.0 – 12.2 mg/dL
72 hours old: 0.0 – 15.6 mg/dL
96 hours to 1 month old: 0.0 – 1.2 mg/dL
Children 1 month and older and
Adults: 0.0 – 1.2 mg/dL
GGT Females: 0 – 60 IU/L
Males: 0 – 65 IU/L
ALT (SGPT) Females: 0 - 40 IU/L
Males: 0 – 55 IU/L
Quantitative results of 6 biochemical tests are analyzed using a
computational algorithm to provide a quantitative surrogate marker
(0.0-1.0) for liver fibrosis (METAVIR F0-F4) and for
necroinflammatory activity (METAVIR A0-A3).
0.74 = Stage F4 – Cirrhosis
Macroinflamm Activity Scoring:
0.62 = Grade A3 – Severe activity
The negative predictive value of a Fibrotest score 0.48 (F2, 3, 4) was 61% in that same patient
cohort. HCV FibroSURE is not recommended in patients with
Gilbert Disease, acute hemolysis (e.g. HCV ribavirin therapy
mediated hemolysis), acute hepatitis of the liver, extra-hepatic
cholestasis, transplant patients, and/or renal insufficiency patients.
Any of these clinical situations may lead to inaccurate quantitative
predictions of fibrosis and necroinflammatory activity in the liver.
The performance characteristics of this test have been
determined by LabCorp. This test has not been cleared or
approved by the U.S. Food and Drug Administration (FDA).
The FDA has determined that such clearance or approval is not
currently required. LabCorp is regulated under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA) and is
certified to perform high complexity testing.
Results and Interpretation Provided By:
1912 Alexander Drive
Research Triangle Park, NC 27709
Test Performed By: Lab-Corp Burlington
1447 York Court
Burlington, NC 27215-2230
within 2 years I had 3 hepa-score by Quest and one Fibrosure by Labcorp. My results in the beginning were F-0 F-1 with Quest. Then I had the Fibrosure came back F-4 cirrhosis. Then the final Hepascore came back F-2. From the date of my diagnosis in 09 until Feb 2011, I had these done approx every 6 months. I finally got a biopsy in March 2011 right before I started treatment and it came out F2. The blood markers are not that reliable sorry to say. Neither is anything a for sure bet, but the biopsy is still more reliable. I didnt look at your status to see for any prior posts about your treatment history, but if you are on the fence between a 1 and 2. It is getting near the time to start treatment. Best Wishes
I would also add that if you cant have a biopsy for medical reasons, then yes, by all means the fibrosure/hepascore and or catscan would be the alternatives to get some info on the condition of your liver.
ok I see you are getting ready to start treatment! Im so glad for you and wish you the best. One thing is a lot of people who cure the HCV also can turn back their liver damage a stage or two!
thanks so much there is still no much confusion about everything but getting better and better with everyones help and sometimes overwhelming.